Anti-AVR2B/ ACVR2B/ ACTRIIB monoclonal antibody
Anti-AVR2B/ ACVR2B/ ACTRIIB antibody for FACS & in-vivo assay
Go to ACVR2B/ACVR2B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T80338-Ab-1/ GM-Tg-hg-T80338-Ab-2 | Anti-Human ACVR2B monoclonal antibody | Human |
GM-Tg-rg-T80338-Ab-1/ GM-Tg-rg-T80338-Ab-2 | Anti-Rat ACVR2B monoclonal antibody | Rat |
GM-Tg-mg-T80338-Ab-1/ GM-Tg-mg-T80338-Ab-2 | Anti-Mouse ACVR2B monoclonal antibody | Mouse |
GM-Tg-cynog-T80338-Ab-1/ GM-Tg-cynog-T80338-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ACVR2B monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T80338-Ab-1/ GM-Tg-felg-T80338-Ab-2 | Anti-Feline ACVR2B monoclonal antibody | Feline |
GM-Tg-cang-T80338-Ab-1/ GM-Tg-cang-T80338-Ab-2 | Anti-Canine ACVR2B monoclonal antibody | Canine |
GM-Tg-bovg-T80338-Ab-1/ GM-Tg-bovg-T80338-Ab-2 | Anti-Bovine ACVR2B monoclonal antibody | Bovine |
GM-Tg-equg-T80338-Ab-1/ GM-Tg-equg-T80338-Ab-2 | Anti-Equine ACVR2B monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T80338-Ab-1/ GM-Tg-hg-T80338-Ab-2; GM-Tg-rg-T80338-Ab-1/ GM-Tg-rg-T80338-Ab-2; GM-Tg-mg-T80338-Ab-1/ GM-Tg-mg-T80338-Ab-2; GM-Tg-cynog-T80338-Ab-1/ GM-Tg-cynog-T80338-Ab-2; GM-Tg-felg-T80338-Ab-1/ GM-Tg-felg-T80338-Ab-2; GM-Tg-cang-T80338-Ab-1/ GM-Tg-cang-T80338-Ab-2; GM-Tg-bovg-T80338-Ab-1/ GM-Tg-bovg-T80338-Ab-2; GM-Tg-equg-T80338-Ab-1/ GM-Tg-equg-T80338-Ab-2 |
Products Name | Anti-ACVR2B monoclonal antibody |
Format | mab |
Target Name | ACVR2B |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-ACVR2B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Biosimilar | GMP-Bios-ab-069 | Pre-Made Bimagrumab biosimilar, Whole mAb, Anti-ACVR2B Antibody: Anti-ACTRIIB/ActR-IIB/HTX4 therapeutic antibody |
Target Antigen | Products Developing | Multi-species AVR2B/ ACVR2B/ ACTRIIB VLP (virus-like particle) (Products Developing) |
Cytokine | GM-Tg-g-T80338-Ag-1 | activin A receptor, type IIB (ACVR2B) protein |
ORF Viral Vector | pGMLPm003094 | mouse Acvr2b Lentivirus plasmid |
ORF Viral Vector | pGMLPm003095 | mouse Acvr2b Lentivirus plasmid |
ORF Viral Vector | vGMLPm003094 | mouse Acvr2b Lentivirus particle |
ORF Viral Vector | vGMLPm003095 | mouse Acvr2b Lentivirus particle |
Target information
Target ID | GM-T80338 |
Target Name | ACVR2B |
Gene ID | 93,11481,25366,696071,485590,101086087,282131,100053588 |
Gene Symbol and Synonyms | 4930516B21Rik,ActR-IIB,ACTRIIB,ACVR2B,AI047905,HTX4 |
Uniprot Accession | Q13705,P38445,Q95126 |
Uniprot Entry Name | AVR2B_HUMAN,AVR2B_RAT,AVR2B_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, INN Index, Cytokine Target |
Disease | N/A |
Gene Ensembl | ENSG00000114739 |
Target Classification | Kinase |
The target: ACVR2B, gene name: ACVR2B, also named as ACTRIIB, ActR-IIB, HTX4. Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.